Can ArQule’s Tivantinib Cut It? Reasons To Be A Skeptic
Research - Despite continued claims to the contrary, ArQule is a fairly weak MET inhibitor, and some publications question this proposed mechanism entirely
Premium: Read NowzPremium
Merry Christmas! Watch Our December Webinar
Research - A recording of last night’s webinar is available for your leisurely viewing this holiday weekend. Last night Mr. King focused primarily on January and early … Continue Reading
Premium: Read Now
Revance’s Latest: Incremental Positive, More To Come
Insights - Revance Therapeutics’ (RVNC) cervical dystonia results were released after the bell on Monday. The phase 2 trial was an open-label dose-ranging study to evaluate the … Continue Reading
Premium: Read Now
What’s New With Synergy, Revance, and Sage
Research - Reminder: Our Healthcare Huddle is next Wednesday, Nov 23, at 5:00 ET. We understand that this may conflict with holiday celebrations, so we’ll have a … Continue Reading
Premium: Read Now
ASH Abstracts Are Out, and They’re Not Helping Biopharma
Research - The NASDAQ Biotech Index Fund (IBB) is down 1.5%, the SPDR S&P Biotech ETF (XBI) down 3% and testing its 200-week moving average and current … Continue Reading
Premium: Read NowUpdates on Some Recent Ideas
Research - Marinus Pharmaceuticals (MRNS) finally released top-line results from their small study of ganaxolone in PCDH19 this morning. Recall we covered this in our August webinar … Continue Reading
Premium: Read NowWebinar: This Fall’s Medical Conferences
Research - A recording of last night’s strategy webinar is now available. Click here for the recording. Thanks to those of you who attended on a Thursday … Continue Reading
Premium: Read Now